Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

American Journal of Hematology

Volumn 90, Issue 3, 2015, Pages E40-E43

  González López, Tomás José ^a   Pascual, Cristina ^b   Álvarez Román, María Teresa ^c   Fernández Fuertes, Fernando ^d   Sánchez González, Blanca ^e   Caparrós, Isabel ^f   Jarque, Isidro ^g   Mingot Castellano, María Eva ^h   Hernández Rivas, José Angel ⁱ   Martín Salces, Mónica ^c   Solán, Laura ^b   Beneit, Paola ^j   Jiménez, Reyes ^k   Bernat, Silvia ^l   Andrade, Marcio M ^m   Cortés, Montserrat ⁿ   Cortti, Maria José ^o   Pérez Crespo, Susana ^p   Gómez Núñez, Marta ^q   Olivera, Pavel E ^r   Pérez Rus, Gloria ^b   Martínez Robles, Violeta ^s   Alonso, Rafael ^t   Fernández Rodríguez, Angeles ^u   Arratibel, María Carmen ^v   Perera, María ^w   Fernández Miñano, Carmen ^j   Fuertes Palacio, Miguel Angel ^x   Vázquez Paganini, Juan Andrés ^y   Gutierrez Jomarrón, Isabel ^o   Valcarce, Inés ^r   de Cabo, Erik ^z   Sainz, Adriana ^v   Fisac, Rosa ^aa   Aguilar, Carlos ^ab   Paz Martínez Badas, María ^ac   Peñarrubia, María Jesús ^ad   Calbacho, María ^ae   de Cos, Carmen ^af   González Silva, Manuel ^ag   Coria, Erika ^y   Alonso, Arancha ^ah   Casaus, Alberto ^ai   Luaña, Armando ^aj   Galán, Pilar ^ak   Fernández Canal, Cristina ^al   Garcia Frade, Javier ^am   González Porras, José Ramón ^an   more..

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^j HOSPITAL VEGA BAJA   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^l HOSPITAL DE LA PLANA   (Spain)

^m HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

ⁿ HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^o HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^p University Hospital of Santiago de Compostela   (Spain)

^q HOSPITAL DE SABADELL   (Spain)

^r HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^s HOSPITAL DE LEÓN   (Spain)

^t HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^u HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^v HOSPITAL DONOSTIA   (Spain)

^w HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^x HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^y HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^z HOSPITAL EL BIERZO   (Spain)

^aa HOSPITAL GENERAL DE SEGOVIA   (Spain)

^ab Hospital General del Insalud Soria   (Spain)

^ac HOSPITAL PROVINCIAL DE ÁVILA   (Spain)

^ad HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^ae HOSPITAL RAMÓN Y CAJAL   (Spain)

^af HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^ag Unidad de Enfermedades Infecciosas   (Spain)

^ah HOSPITAL QUIRÓN   (Spain)

^ai HOSPITAL PUNTA DE EUROPA   (Spain)

^aj Universidade de Lleida   (Spain)

^ak Hospital General Mateu Orfila   (Spain)

^al HOSPITAL DE CABUEÑES   (Spain)

^am HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^an HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ELTROMBOPAG; RITUXIMAB; ROMIPLOSTIM; ANTIANEMIC AGENT; BENZOIC ACID DERIVATIVE; HYDRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; THROMBOPOIETIN RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; DIARRHEA; DOSE RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DIAGNOSIS; PRIMARY IMMUNE RESPONSE; PRIMARY IMMUNE THROMBOCYTOPENIA; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; AGONISTS; CHRONIC DISEASE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG MONITORING; ERYTHROPOIESIS; GENETICS; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENT DISEASE; THROMBOCYTE; TREATMENT OUTCOME;

ADULT; AGED; BENZOATES; BLOOD PLATELETS; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; ERYTHROPOIESIS; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HUMANS; HYDRAZINES; MALE; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SPLENECTOMY; TREATMENT OUTCOME;

EID: 84923069786     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23900     Document Type: Article

References (22)

1. Toltl LJ, Arnold DM. Pathophysiology and management of chronic immune thrombocytopenia: Focusing on what matters. Br J Haematol 2011;152:52-60.
2. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-186.
3. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-4207.
4. Sanz MA, Vicente García V, Fernández A, et al. Sociedad Española de Hematología y Hemoterapia; Sociedad Española de Hematología y Oncología Pediátricas. [Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia]. Med Clin (Barc) 2012;138:261.e1-261.e17. (Spanish).
5. Solar GP, Kerr WG, Zeigler FC, et al. Role of c-Mpl in early hematopoiesis. Blood 1998;92:4-10.
6. Debili N, Wendling F, Cosman D, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995;85:391-401.
7. Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: A review of their use in idiopathic thrombocytopenic purpura. Drugs 2008;68:901-912.
8. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-2247.
9. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377:393-402.
10. Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013;121:537-545.
11. 11. Leven E, Miller A, Boulad N, et al. Successful discontinuation of eltrombopag treatment in patients with chronic ITP. Blood (ASH Annual Meeting Abstracts) 2012;120:Abstract 1085.
12. González-López TJ, Sánchez-González B, Pascual C, et al. Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia. Platelets, 2014 Feb 5. [Epub ahead of print] PubMed PMID: 24499036.
13. Newland A, Cervinek L, Eggermann J, et al. Sustained hemostatic platelet counts in adult patients with primary immune thrombocytopenia (ITP) following cessation of romiplostim-Four European case studies. Haematologica 2011;96:98.
14. Bussel JB, Rodeghiero F, Lyons RM, et al. Sustained hemostatic platelet counts in adults with immune thrombocytopenia (ITP) following cessation of treatment with the TPO receptor agonist romiplostim: Report of 9 cases. Blood (ASH Annual Meeting Abstracts) 2011;118:Abstract 3281.
15. Vlachaki E, Papageorgiou V, Klonizakis F, et al. Total remission of severe immune thrombocytopenia after short term treatment with romiplostim. Hematol Reports 2011;3:e20.
16. Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion 2013;53:2807-2812.
17. Bussel JB, Wang X, Eisen M. Case studies of remission in adults with immune thrombocytopenia (ITP) following cessation of treatment with the TPO receptor agonist romiplostim. Blood (ASH Annual Meeting Abstracts) 2013;122:Abstract 328.
18. Mahévas M, Fain O, Ebbo M, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol 2014;165:865-869.
19. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-2893.
20. Bussel JB, Saleh MN, Vasey SY, et al. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). Br J Haematol 2013;160:538-546.
21. Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010;116:4639-4645.
22. Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin Hematol 2010;47:243-248.